Drug application
KYNMOBI (APOMORPHINE HYDROCHLORIDE)
Drugs@FDA NDA 210875 · SUMITOMO PHARMA AM
Key facts
| Drug name | KYNMOBI |
|---|---|
| Active ingredients | APOMORPHINE HYDROCHLORIDE |
| Application type | NDA |
| Application number | 210875 |
| Company | SUMITOMO PHARMA AM |
| Dosage forms | FILM, SUBLINGUAL |
| Strength | 10MG |
| Marketing status | Discontinued |
| Reference listed drug | Yes |
| Latest submission class | Type 3 - New Dosage Form |
| Latest submission status date | May 21, 2020 |
At a glance
- 1–9 Submissions
- 1–9 Supplements
- 1–9 Label versions
- 1–9 Products
- None Therapeutic equivalents
- Yes FDA letters on file
- Yes FDA reviews on file
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Drugs@FDA applications
Drugs@FDA covers FDA-approved brand-name and generic drugs and therapeutic biologics, with their applications (NDA, ANDA or BLA), products, submissions and labels.
Source: U.S. Food and Drug Administration (FDA), Drugs@FDA · Source date: